Article révisé par les pairs
Résumé : Breast cancer is frequently diagnosed in older women, yet treatment standards are based largely on clinical trials conducted in younger women. Survival outcomes for breast cancer in older women are suboptimal, partly because of underuse of appropriate therapy. Capecitabine is an oral fluoropyrimidine with a favorable side effect profile that is an attractive therapeutic option for older breast cancer patients. However, dose adjustments for renal function and careful monitoring of adherence, potential drug interactions, and toxicity are particularly important in this population. The article reviews the safety and efficacy data from studies with capecitabine monotherapy or capecitabine in combination with other therapies for breast cancer, with a particular focus on elderly patients. © 2010 Elsevier Inc.